Few natural history studies are available which describe long-term outcomes after venous thromboembolism. However, symptomatic deep-vein thrombosis (DVT) of the lower extremities carries a high risk for recurrent venous thromboembolism that persists for many years. This risk is higher among patients with permanent risk factors including inherited abnormalities of hemostasis than among patients who have suffered trauma or who are postoperative. The development of recurrent ipsilateral DVT carries a high risk for severe postthrombotic syndrome, an otherwise rare problem in patients with a first episode of DVT adequately treated with anticoagulant drugs and wearing vascular compression stockings. Long-term survival following DVT is generally good in the absence of malignancy. Carefully designed randomized trials are needed to determine whether chronic anticoagulation can reduce further the risks of recurrent DVT and symptoms of post-thrombotic syndrome.
Introduction
While abundant information is available describing shortterm prognosis following deep-vein thrombosis (DVT), limited and conflicting results are available regarding the long-term clinical course of this disease. Recurrent thromboembolism and post-thrombotic syndrome (PTS) are the most important long-term complications of DVT. Thromboembolic complications are reported to occur with a frequency of approximately 5% during the first 3 months of anticoagulant treatment and are related to the intensity and duration of initial heparinization. The clinical signs and symptoms of PTS become manifest in the months and years that follow. Unfortunately, data are limited concerning the true frequency of PTS since most evidence is based on small retrospective studies.
This paper reviews those studies that describe the natural history of DVT. The only studies included were those in which patients with confirmed DVT were prospectively followed to document recurrent thromboembolic events or PTS. Efforts were made to identify all trials, both published and unpublished, addressing the long-term clinical history of DVT in symptomatic patients. This included a Medline search, reviewing bibliographies of appropriate publications, and searching recent journals using Current Contents to find reports that may not have been included in Medline data bases. Studies that were duplicate reports or preliminary reports which were later presented in full were excluded. The clinical outcome variables reviewed here are recurrent thromboembolism, prevalence of PTS and allcause mortality. a The Institute of Medical Semeiotics, University Hospital of Padua, Italy and b The Academic Medical Centre, Amsterdam, The Netherlands
Recurrent thromboembolism
Patients with DVT are usually treated with an initial course of heparin (5-10 days) followed by 3-6 months of oral anticoagulant therapy. This treatment regimen reduces the risk for short-term thromboembolic complications to approximately 5%. Schulman et al performed a multicenter trial comparing 6 weeks versus 6 months of oral anticoagulant therapy in 897 patients who had suffered a first episode of venous thromboembolism (VTE). 1 After 2 years of follow-up, there were 80 recurrences among the 443 patients randomized to the 6-week group (18.1%) and 43 among the 454 randomized to the 6-month group (9.5%). The odds ratios for recurrence in the 6-week group was 2.1 (95% CI, 1.4-3.1). This trial showed, therefore, a substantial reduction in the risk for recurrent thromboembolism among patients receiving 6 months of anticoagulation. However, there was no difference in the incidence of recurrent events in the two groups from 6-24 months after the initial episode in both groups of patients. Indeed, in both groups, there was a linear increase in risk after cessation of anticoagulation, corresponding to a 5-6% incidence annually. Furthermore, although there was a trend towards a higher rate of recurrence among patients with temporary risk factors in the 6week group than in the 6-month group (8.6% versus 4.8%), the overall rate of recurrence after 2 years was much lower among patients with temporary risk factors than among those with permanent risk factors (6.6% versus 18%).
In a small prospective 12-year follow-up study of Swiss patients with symptomatic DVT, venous thromboembolic recurrent events were observed in 14 (24%) of 58 patients. 2 None of these patients had malignancy or well-recognized risk factors for venous thrombosis. Further, in a prospective randomized study addressing the effect of elastic stockings for prevention of PTS, recurrence of VTE was recorded in 14 (14.6%) of the 96 patients in the stocking group, and in 13 (13.3%) of the 98 patients in the control group over a 5-year follow-up period. 3 The long-term incidence of recurrent venous thromboembolism was additionally determined in 355 consecutive patients with a first episode of DVT confirmed by venography. 4 Patients were followed over a period of 8 years and were treated with an initial course of full-dose heparin, followed by at least 3 months of oral anticoagulants. Followup assessments were scheduled at 3 and 6 months, and then every 6 months until 8 years. Diagnosis of recurrent VTE was adjudicated according to standard criteria. After cessation of anticoagulation, a high risk of recurrent venous thromboembolic disease was found, resulting in a cumulative incidence of 30% after 8 years of follow-up ( Figure  1 ). One of every five recurrent episodes was pulmonary embolism (which was fatal in more than half), and approximately one-third of the recurrent leg vein thromboses were in the previously asymptomatic leg.
Patients with underlying malignancy, or defects that impaired coagulation inhibition (antithrombin, protein C and S defects, lupus-like anticoagulants) were at a statistically significant higher risk for recurrences than patients without these features (risk ratio (RR), 1.7 and 1.4, respectively). As expected, a considerable number of patients suffered DVT following surgery or trauma. The findings that these patients were at a significantly lower risk for recurrent VTE (RR, 0.4 and 0.5, respectively) indicates that these conditions are transient risk factors for DVT.
The presence of factor V Leiden was subsequently determined in 251 surviving patients of the previous cohort free from malignancies or other confirmed abnormalities in the coagulation or fibrinolytic system. 5 This mutation was detected in 41 patients (16.3%). The cumulative incidence of recurrent thromboembolism in carriers of factor V Leiden mutation after 8 years was 39.7% versus 18.3% in patients free from this abnormality (RR, 2.4; 95% CI, 1.3 to 4.5; p Ͻ 0.01). These data confirm prior findings from the Physicians' Health Study 6 in which a group of 77 men with a history of venous thromboembolism not associated with surgery, cancer or trauma, was followed prospectively over a period of 5 years. In that study, the overall rate of recurrence was 2.5 events per 100 person years of followup. However, the recurrence rate was significantly higher among those with factor V Leiden compared with those without this mutation (7.46 versus 1.82 events per 100 person years of follow-up, p = 0.04). Thus, in this study, those with factor V Leiden had a fourfold increase in risk of recurrent events. In contrast, recurrent VTE was extremely uncommon in the Physicians' Health Study among patients who had DVT in association with surgery or trauma. Indeed, among such patients, the association between factor V Leiden and VTE was no longer statistically significant. 7 What do these findings imply for the management of patients with DVT? The observed difference in recurrence rates between patients with and without reversible risk factors is relevant to the issue of optimal duration of oral anticoagulant therapy. 8, 9 The long-term prognosis of patients in whom DVT occurs following exposure to temporary risk factors (i.e. recent surgery, trauma or fracture) is excellent. Accordingly, these patients may not require further anticoagulation following the initial 3-month period.
In contrast, in patients with malignancy and in those with either hereditary or acquired thrombophilia, the incidence of long-term recurrent thromboembolism is high. Accordingly, longer-term anticoagulation may be considered in these patients, particularly when there is a history of recurrent episodes of VTE.
There is insufficient evidence to support a life-long treatment for patients suffering a first idiopathic venous thrombosis, since the risks of full dose warfarin over long periods of time can be substantial. Randomized trials are therefore needed to explore the benefit to risk ratio of prolonged anticoagulation beyond the currently recommended 3-6month period in patients presenting with a first episode of spontaneous DVT.
Post-thrombotic syndrome
Post-thrombotic syndrome (PTS) is probably caused by a combination of venous hypertension, resulting from persisting venous obstruction and venous valve damage, and abnormal microcirculation. 10 The incidence of PTS following confirmed DVT is unknown, but has been reported to be between 20% and 100%. To date, studies of PTS have been small or retrospective, and the lack of objective diagnostic criteria for PTS makes comparison of these studies difficult. Further, in all studies, the potential for bias was high due to either the selection of patients with extensive thrombotic disease or to failure to distinguish postthrombotic sequelae from recurrent venous thrombosis.
Recently, the results of a prospective randomized study on the prevention of PTS in patients with DVT have become available. In this study, 194 consecutive patients with confirmed proximal-vein thrombosis were allocated to usual care or to elastic commercial stockings. 3 The study was designed to have at least 5 years of follow-up. A predefined scoring system was used to classify two categories of patients: mild-to-moderate PTS and severe PTS. Median follow-up was 76 months in both groups. Mild-to-moderate PTS occurred in 19 (20%) of the 96 patients with stockings, and in 46 (47%) of the 98 patients without stockings (p Ͻ 0.001). Eleven (11.5%) patients in the stocking group developed severe PTS, while this occurred in 23 (23.5%) patients without stockings (p Ͻ 0.001). In both groups, the majority of PTS cases was documented within the first 24 months after the thrombotic event. Extent of initial thrombus on venography was not related to the development of PTS.
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The long-term incidence of PTS was determined in a large cohort of consecutive symptomatic patients with a first episode of venographically proven DVT. 4 All patients were treated with full-dose heparin followed by at least 3 months of oral anticoagulation, and were instructed to wear compression elastic stockings as soon as possible after hospital discharge. At each follow-up visit over a 2-year period, the severity of post-thrombotic signs and symptoms was scored using a standardized scale. Five subjective symptoms (heaviness, cramps, pruritis, paresthesia, pain) and six objective signs (induration of the skin, edema, hyperpigmentation, redness, pain during calf compression, new venous ectasia) were assessed using a score between 0 and 3. In addition, the presence of ulceration of the leg was evaluated. A patient was defined as having severe PTS if ulceration of the leg was observed or if a score higher than 15 was obtained on a single occasion. Mild-to-moderate PTS was defined if, on two consecutive follow-up visits, a score from 5 to 14 was reached. All other patients were considered not to have PTS. The score was determined in all patients by a single trained physician who was unaware of the results of the previous evaluations. The validity of this standardized scale, its reproducibility and its correspondence with a patient's quality of life have been demonstrated in a prospective study. 11 Of the 344 patients, 84 developed PTS. Of these, 25 (30%) had severe post-thrombotic manifestations. The cumulative incidence of the PTS was 18% after 1 year and 24.5% after 2 years of follow-up. Thereafter, the incidence of the PTS increased gradually until reaching a plateau at about 30% after 5 years. Considering only severe postthrombotic manifestations, a slightly different pattern was seen: the cumulative incidence increased gradually from 2.7% after 1 year to 8.1% after 5 years (Figure 2 ). Postthrombotic manifestations usually became apparent within the first 2 years following an acute episode of DVT. These findings challenge the general view that PTS requires a long time period to become manifest and are in agreement with those of the Dutch study. 3 Severe PTS was relatively rare following an episode of venous thrombosis in patients wearing elastic compression stockings and adequately treated with anticoagulants. This low incidence of post-thrombotic manifestations is in clear contrast with the results of most available studies on PTS, reporting a risk of severe long-term sequelae in as many as 50-70% of patients with an acute episode of DVT. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] These conclusions are supported by the findings of another recent study in which a cohort of 58 consecutive patients with DVT was prospectively followed for 12 years. 2 During this long follow-up period, only one patient developed severe PTS, while 37 patients had both clinical and hemodynamic normal findings. In view of the low absolute incidence of severe PTS found in the recent studies, surgical thrombectomy or thrombolysis should be reserved for special circumstances.
Although it was expected that the extent of the initial thrombosis and the degree of thrombus occlusiveness would be related with the risk of developing PTS, this has not been demonstrated consisently. 3, 4 Thus, patients with minor proximal DVT and those with isolated calf-vein thrombosis were as likely to develop late sequelae as patients with extensive thrombosis involving the entire venous system of the thigh and pelvis. The explanation for this observation is uncertain. However, the development of ipsilateral recurrent DVT was associated with increased risk for PTS. Prevention of recurrent thrombosis with long-term anticoagulation might thus represent a method to prevent severe PTS.
Mortality
Short-term mortality (3-6 months) for patients suffering an episode of DVT is reported to range between 7% and 15%. [23] [24] [25] [26] [27] [28] [29] Causes of death include cancer, pulmonary embolism and major bleeding. However, cancer accounts for the large majority of patients who die within the first months after DVT, indicating that patients free of oncologic disease generally have good prognosis. [23] [24] [25] [26] [27] [28] [29] Recently, the long-term mortality of patients with DVT was documented. 3 In a Dutch study of 355 patients, 90 died during follow-up. Causes of death in this study included malignancy (n = 52), pulmonary embolism (n = 9), acute myocardial infarction or heart failure (n = 5), ischemic stroke (n = 10), anticoagulant related hemorrhage (n = 2) and other miscellaneous etiologies (n = 6). In six patients who died suddenly, a definitive diagnosis could not be made.
Overall, survival was 83.3% after 1 year and 80.1% after 2 years of follow-up. After 5 and 8 years, the survival was 74.6% and 70.2%, respectively (Figure 3) . The presence of malignancy increased the risk of death remarkably (RR = 8.1). Other clinical features showed no association with mortality.
Mortality occurred mainly during the first year in patients with underlying malignancy. In fact, most patients who died did so because of a neoplastic disorder already known at the time of a patient's presentation or which became manifest soon after. In patients without malignant disorders, total mortality was low, supporting the view that current therapeutic approaches to patients with venous thrombosis are effective and safe. These results also confirm previous observations of a strong relationship between cancer and thrombosis. 30, 31 However, whether extensive diagnostic evaluation for occult malignancy is justified at the time of referral for idiopathic DVT, remains uncertain.
